干细胞：一种用于1型糖尿病的新兴新型疗法。

Stem cells: An emerging novel therapeutic for type-1 diabetes mellitus.

作者信息

Thakkar Umang G, Vanikar Aruna V, Trivedi Hargovind L

机构信息

Department of Regenerative Medicine and Stem Cell Therapy and Pediatrics, G.R. Doshi and K.M. Mehta Institute of Kidney Diseases & Research Centre (IKDRC), Dr. H.L. Trivedi Institute of Transplantation Sciences (ITS), India; Department of Pathology, Laboratory Medicine, Transfusion Services and Immunohematology, G.R. Doshi and K.M. Mehta Institute of Kidney Diseases & Research Centre (IKDRC), Dr. H.L. Trivedi Institute of Transplantation Sciences (ITS), India.

出版信息

Diabetes Res Clin Pract. 2017 Aug;130:130-132. doi: 10.1016/j.diabres.2017.04.014. Epub 2017 Apr 19.

DOI:10.1016/j.diabres.2017.04.014

PMID:28618324

Abstract

Stem cell based strategies are therapeutically potent for treating type-1 diabetes mellitus owing to their intrinsic regenerative capacity and immunomodulatory properties to arrest autoimmune β-cell destruction, preserve residual β-cell mass, facilitate endogenous regeneration, ameliorate innate/ alloimmune graft rejection, restore β-cell-specific unresponsiveness in absence of chronic immunosuppression and to reverse hyperglycemia.

摘要

基于干细胞的策略在治疗1型糖尿病方面具有治疗潜力，这归因于它们固有的再生能力和免疫调节特性，能够阻止自身免疫性β细胞破坏、保留残余β细胞量、促进内源性再生、改善先天性/同种免疫移植排斥反应、在无慢性免疫抑制的情况下恢复β细胞特异性无反应性并逆转高血糖。